Omnicell (NASDAQ:OMCL)‘s stock had its “buy” rating reiterated by investment analysts at Cantor Fitzgerald in a research report issued on Tuesday. They presently have a $60.00 target price on the stock. Cantor Fitzgerald’s price target indicates a potential upside of 17.65% from the company’s previous close.

OMCL has been the topic of several other reports. Benchmark lifted their target price on shares of Omnicell from $55.00 to $67.00 and gave the stock a “buy” rating in a research note on Tuesday, September 5th. Zacks Investment Research downgraded shares of Omnicell from a “hold” rating to a “strong sell” rating in a research note on Wednesday, November 1st. Oppenheimer reaffirmed a “buy” rating and issued a $55.00 target price on shares of Omnicell in a research note on Thursday, October 19th. Finally, Craig Hallum reaffirmed a “buy” rating and issued a $62.00 target price (up from $52.00) on shares of Omnicell in a research note on Monday, October 30th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $55.14.

Omnicell (OMCL) opened at $51.00 on Tuesday. The company has a current ratio of 1.53, a quick ratio of 1.08 and a debt-to-equity ratio of 0.38. Omnicell has a one year low of $31.85 and a one year high of $55.40.

Omnicell (NASDAQ:OMCL) last issued its earnings results on Thursday, October 26th. The company reported $0.42 EPS for the quarter, hitting the consensus estimate of $0.42. Omnicell had a negative net margin of 0.51% and a negative return on equity of 0.79%. The company had revenue of $186.78 million for the quarter, compared to the consensus estimate of $192.45 million. During the same period in the previous year, the firm earned $0.40 earnings per share. The firm’s revenue for the quarter was up 5.7% on a year-over-year basis. research analysts forecast that Omnicell will post 0.12 EPS for the current year.

In other Omnicell news, EVP Dan S. Johnston sold 14,613 shares of the business’s stock in a transaction on Friday, November 17th. The shares were sold at an average price of $47.81, for a total transaction of $698,647.53. Following the transaction, the executive vice president now directly owns 43,621 shares of the company’s stock, valued at approximately $2,085,520.01. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Robin Gene Seim sold 9,780 shares of the business’s stock in a transaction on Friday, September 15th. The shares were sold at an average price of $48.97, for a total transaction of $478,926.60. Following the transaction, the executive vice president now directly owns 55,896 shares in the company, valued at $2,737,227.12. The disclosure for this sale can be found here. Over the last three months, insiders have sold 38,944 shares of company stock worth $1,889,592. Insiders own 3.77% of the company’s stock.

Institutional investors have recently modified their holdings of the business. BlackRock Inc. boosted its holdings in shares of Omnicell by 2.3% during the 2nd quarter. BlackRock Inc. now owns 4,589,119 shares of the company’s stock valued at $197,790,000 after buying an additional 101,776 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of Omnicell by 3.7% during the 2nd quarter. Vanguard Group Inc. now owns 1,928,201 shares of the company’s stock valued at $83,105,000 after buying an additional 67,902 shares in the last quarter. Conestoga Capital Advisors LLC boosted its holdings in shares of Omnicell by 0.7% during the 3rd quarter. Conestoga Capital Advisors LLC now owns 1,617,706 shares of the company’s stock valued at $82,584,000 after buying an additional 11,105 shares in the last quarter. Oak Ridge Investments LLC boosted its holdings in shares of Omnicell by 0.6% during the 2nd quarter. Oak Ridge Investments LLC now owns 1,537,940 shares of the company’s stock valued at $66,285,000 after buying an additional 8,491 shares in the last quarter. Finally, Janus Henderson Group PLC boosted its holdings in shares of Omnicell by 129.6% during the 2nd quarter. Janus Henderson Group PLC now owns 1,231,933 shares of the company’s stock valued at $53,096,000 after buying an additional 695,334 shares in the last quarter. 99.84% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “Omnicell (OMCL) Stock Rating Reaffirmed by Cantor Fitzgerald” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another domain, it was illegally stolen and republished in violation of US and international copyright legislation. The original version of this piece can be accessed at https://www.thecerbatgem.com/2017/12/07/omnicell-omcl-stock-rating-reaffirmed-by-cantor-fitzgerald.html.

About Omnicell

Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.

Analyst Recommendations for Omnicell (NASDAQ:OMCL)

Receive News & Stock Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related stocks with our FREE daily email newsletter.